CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
D-cycloserine +1 moredrug
Likely dose
D-cycloserine 50 mg, 100 mg, or 200 mg twice dailyAI-extracted
Key inclusion· 4
  • History of low back pain for at least 6 months, with or without radiation to leg or buttocks
  • Age 18 years or older
  • Visual analogue scale pain score greater than 50 mm
  • Generally stable health
Key exclusion· 12
  • Low back pain associated with systemic signs or symptoms (fever, chills)
  • Evidence of rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures, fibromyalgia, history of back surgery or tumor
  • Active litigation, disability claim, or workers' compensation related to back pain
  • Neurologic disorder, including history of seizures

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00125528
NCT00125528Phase 2Completed

D-Cycloserine in the Management of Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Pilot Study

Thomas J. Schnitzer·interventional·Posted Aug 1, 2005·Updated Feb 9, 2017

In Brief

A Phase 2 clinical trial evaluating D-cycloserine and placebo for Low Back Pain and Pain. Completed, enrolled 41 participants across 1 site.

Detailed Summary

Pre-clinical studies in rats suggest that D-cycloserine (DCS) is effective in the management of chronic neuropathic pain. This pilot study will attempt to determine the effect of D-cycloserine in the treatment of chronic low back pain. Other aims of this study are to determine the safety of D-cycloserine in the treatment of chronic low back pain and to determine which pain measurement scales are best at measuring the efficacy of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLow Back Pain, Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2005
Enrollment StartJul 1, 2012
Primary CompletionApr 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.9 years ago

Interventions

D-cycloserinedrug

D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid

placebodrug

placebo bid